Nuclein, LLC
- Aug 14, 2026 · D/A · $9,253,488 sold of $16,114,842 · 15 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Jun 22, 2026 · D · $1,295,000 sold of $11,114,842 · 2 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Apr 27, 2026 · D/A · $19,065,157 sold of $25,000,000 · 49 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Feb 5, 2026 · D/A · $9,392,180 sold of $15,000,000 · 34 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Dec 17, 2025 · D/A · $14,904,000 sold of $20,000,000 · 42 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Oct 14, 2025 · D/A · $9,779,000 sold of $15,000,000 · 37 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Jun 30, 2025 · D · $0 sold of $10,000,000 · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Feb 3, 2025 · D · $750,000 sold of $15,000,000 · 3 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
- Mar 23, 2023 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
Raised $19.1M from 49 investors (100% of the $16.1M target) as of the latest filing. Jeffrey is listed as executive officer on 9 filings for this deal.
Sources
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.